Gujarat Kidney FY26 Results: Standalone revenue up 14%, PAT rises 9%

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Standalone revenue grew 14% YoY to ₹4,010.02 lakh for FY26
  • Net profit after tax rose 8.7% to ₹990.14 lakh
  • Consolidated revenue more than doubled to ₹8,201.34 lakh due to acquisitions
  • IPO raised ₹250.80 crore; ₹190.23 crore utilized by March 2026
powered bylight_fuzz_icon
49976539

*this image is generated using AI for illustrative purposes only.

Gujarat Kidney and Superspeciality reported a 14% increase in standalone revenue to ₹4,010.02 lakh for the fiscal year ended March 31, 2026. Standalone profit after tax rose 8.7% to ₹990.14 lakh from ₹910.90 lakh in the previous year.

The company consolidated its expansion through an Initial Public Offering (IPO) that raised ₹250.80 crore in December 2025. Consolidated revenue more than doubled to ₹8,201.34 lakh, driven by acquisitions of Harmony Medicare, Parekhs Hospital, and other entities during the year.

Financial Performance

Standalone profit before tax grew 3.7% to ₹1,254.70 lakh. Total expenses rose to ₹2,804.77 lakh from ₹2,318.43 lakh, reflecting higher professional fees and expected credit losses.

Metric FY26 (₹ Lakh) FY25 (₹ Lakh) Change
Revenue 4,010.02 3,516.70 +14.0%
Profit Before Tax 1,254.70 1,209.67 +3.7%
Profit After Tax 990.14 910.90 +8.7%

Consolidated net profit attributable to owners of the company reached ₹1,549.69 lakh, up from ₹941.31 lakh in FY25. The group recorded total comprehensive income of ₹1,678.22 lakh.

IPO Utilization

The company utilized ₹190.23 crore of the ₹250.80 crore raised through the IPO as of March 31, 2026. Funds were deployed for acquiring Parekhs Hospital (₹77.00 crore), Ashwini Medical Centre (₹12.40 crore), and additional stake in Harmony Medicare (₹10.78 crore). ₹74.82 crore was used for inorganic growth and general corporate purposes.

What the Numbers Show

While standalone revenue grew steadily at 14%, the consolidated revenue surge to over ₹8,200 lakh indicates significant contribution from newly acquired entities. The acquisition of goodwill totaling ₹9,073.21 lakh on a consolidated basis suggests premium valuations paid for these hospital chains. Operating cash flow from standalone activities turned negative at -₹745.86 lakh, primarily due to a ₹607.78 lakh increase in trade receivables, signaling potential collection pressure amidst rapid expansion.

Historical Stock Returns for Gujarat Kidney and Super Speciality

1 Day5 Days1 Month6 Months1 Year5 Years
+1.91%+12.58%+34.71%+55.35%0.0%0.0%

How will the negative standalone operating cash flow and rising trade receivables impact the company's liquidity as it integrates newly acquired hospitals?

What is the expected timeline for the acquired entities like Parekhs Hospital and Harmony Medicare to achieve synergies that offset the high goodwill valuation?

Will the remaining ₹60.57 crore from the IPO proceeds be allocated for further inorganic expansion or debt reduction to strengthen the balance sheet?

Gujarat Kidney and Super Speciality
View Company Insights
View All News
like19
dislike

Gujarat Kidney and Super Speciality schedules 7th AGM for September 28

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Gujarat Kidney and Super Speciality holds its 7th AGM on September 28, 2026
  • The meeting takes place in physical mode starting at 9:30 am
  • Notices sent electronically to registered shareholders as on August 28, 2026
  • Remote e-voting and ballot paper options available for all members
powered bylight_fuzz_icon
49795184

*this image is generated using AI for illustrative purposes only.

Gujarat Kidney and Super Speciality has scheduled its seventh Annual General Meeting (AGM) for Monday, September 28, 2026. The meeting will commence at 9:30 am in physical mode.

The company notified the BSE and NSE on September 1, 2026, regarding the pre-advertisement notice for the gathering. This disclosure complies with Regulations 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The AGM aims to transact business as outlined in the official notice. Members whose email addresses are registered with the company, depository participants, or the Registrar and Share Transfer Agent as on Friday, August 28, 2026, will receive the notice and annual report electronically.

Shareholders who have not registered their email addresses will receive a letter containing a web link and QR code to access the annual report for FY26. This process adheres to Regulation 36(1)(b) of the SEBI Listing Regulations.

Voting Procedures

Members can cast votes through remote e-voting or via ballot paper during the meeting. Those attending physically who have not voted remotely remain eligible to vote using ballot papers.

The company encourages members holding shares in physical form to dematerialize their holdings or register their details with MUFG Intime India Private Limited. Demat holders are advised to update their contact information with respective depository participants to ensure receipt of electronic communications.

Historical Stock Returns for Gujarat Kidney and Super Speciality

1 Day5 Days1 Month6 Months1 Year5 Years
+1.91%+12.58%+34.71%+55.35%0.0%0.0%

What specific strategic initiatives or capital allocation plans are expected to be proposed at the AGM for the upcoming fiscal year?

How might the company's FY26 financial performance, as detailed in the annual report, influence its dividend payout ratio and shareholder returns?

Are there any anticipated changes to the board of directors or key management positions that could impact Gujarat Kidney and Super Speciality's long-term governance?

Gujarat Kidney and Super Speciality
View Company Insights
View All News
like17
dislike

More News on Gujarat Kidney and Super Speciality

1 Year Returns:0.00%